Enhancing Neuroimaging Insights: LVV & ICV Quantification and Midline Shift Indexing with NeuroQuant CT

In the fast-paced realm of neurocritical care and neurosurgery, time-sensitive and precise diagnostic imaging can mean the difference between rapid intervention and devastating outcomes. Among the critical metrics derived from brain imaging, Lateral Ventricle Volume (LVV), Intracranial Volume (ICV), and Midline Shift (MLS) Index play pivotal roles in assessing and managing conditions like traumatic brain injury (TBI), stroke, hydrocephalus, and mass effect due to intracranial lesions. Thanks to advancements in imaging analytics and AI-driven automation, these volumetric and morphometric measures can now be rapidly quantified, offering clinicians a real-time window into intracranial pathology. 

Critical Imaging Metrics

Lateral Ventricle Volume (LVV)
Changes in LVV can indicate a wide range of neurological issues, from hydrocephalus (ventricular enlargement) to ventricular compression due to mass effect. Quantifying LVV on CT offers: 

  • Objective markers for ventricular asymmetry 
  • Early detection of hydrocephalus or hemorrhagic ventricular compression 
  • Longitudinal monitoring in ICU patients 
  • Automated measurement enables reproducibility, which is essential in serial scans where subtle volumetric changes are clinically significant 

Intracranial Volume (ICV)
ICV encompasses the entire volume enclosed by the cranial cavity – brain tissue, CSF, and blood. It’s a baseline metric against which other volumes (like LVV or lesions) are normalized. ICV quantification provides insights into: 

  • Adjusting LVV and lesion burden measurements for head size variability 
  • Aiding in patient-specific assessments of intracranial compliance 
  • Enhancing risk stratification in global cerebral edema or herniation syndromes 
  • Providing a reliable reference for normalized values (e.g., LVV-to-ICV ratio) through automated ICV segmentation 

Midline Shift (MLS) Index
The MLS index quantifies the degree to which midline brain structures have been displaced from their anatomical center, typically due to mass effect from hemorrhage, edema, tumor, or trauma. Automated MLS indexing provides: 

  • Precise, millimeter-scale quantification of midline deviation 
  • Early alerts for neurosurgical intervention thresholds (e.g., >5 mm shift) 
  • Consistent measurement across serial imaging, overcoming inter-reader variability 
  • A more holistic picture of the spatial and volumetric changes occurring within the cranium by combining MLS with LVV and ICV 

Clinical Impact of Speed and Precision

In acute scenarios, every minute counts – and NeuroQuant CT provides automatic calculations of lateral ventricle volume and intracranial volume (ICV) within minutes of scan acquisition. These metrics are especially valuable when assessing conditions like hydrocephalus, cerebral atrophy, traumatic brain injury, or mass effect, where changes in ventricular size or overall brain volume may influence management. Automating these measurements removes the need for manual ROI placement or time-consuming visual estimation, delivering consistent, quantitative data that can be tracked over time or used to support urgent clinical decisions. 

By replacing manual measurement with a consistent, objective calculation, MLS supports radiologists in quickly identifying mass effect and determining urgency. In clinical practice, a midline shift greater than 5 mm is often considered significant, helping to guide further management or intervention.[1] 

Together, these quantitative imaging biomarkers support: 

  • Rapid triage in emergency departments by flagging critical shifts or ventricular compression 
  • Treatment planning and monitoring for neurosurgical procedures or CSF diversion strategies 
  • Objective communication across care teams, especially in neuro-intensive care 

NeuroQuant CT: Precision in Action!

One of the standout features of NeuroQuant CT is its ability to automatically generate quantitative reports that include measures of ventricular volume, intracranial volume, midline shift, and change over time if a prior exam exists.  

Cortechs.ai | Enhancing Neuroimaging Insights: LVV & ICV Quantification and Midline Shift Indexing with NeuroQuant CT

An axial series with color-coded segmentation of the CSF spaces is also provided, with green denoting CSF in the lateral ventricles. The color-coded images may be used to confirm that the automated segmentation has correctly identified CSF in the ventricles. The lateral ventricular volume (LVV) only includes voxels with CSF density, so volume of blood or a mass in the ventricle (e.g., calcification), will not count towards the total volume measured by NeuroQuant CT. 

Cortechs.ai | Enhancing Neuroimaging Insights: LVV & ICV Quantification and Midline Shift Indexing with NeuroQuant CT

Thanks to advancements in imaging analytics and AI-driven automation, these volumetric and morphometric measures can now be rapidly quantified from non-contrast CT scans—offering clinicians a real-time window into intracranial pathology. By combining speed and precision, NeuroQuant CT helps radiologists respond quickly and confidently in time-sensitive situations, ultimately enhancing diagnostic confidence, efficiency, and accuracy. 

References

[1] Hacking C, Campos A, Alhusseiny K, et al. Midline shift. Reference article, Radiopaedia.org https://doi.org/10.53347/rID-37110

More Resources

09/18/2026

What a Head CT Can and Can’t Tell You About a Concussion

For Concussion Awareness Day, learn how quantitative CT analysis can help measure subtle structural changes and support follow-up after traumatic brain injury.

09/09/2026

Prostate Cancer Awareness Month: Finding the Cancer That Matters

How quantitative MRI can bring greater clarity to decisions across the prostate cancer journey.

09/01/2026

Quantifying What Matters: Advancing Alzheimer’s Imaging with NeuroQuant®

Explore how quantitative imaging is transforming Alzheimer’s care, from structural volumetrics and amyloid PET to treatment monitoring with NeuroQuant®.

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation
Scroll to Top